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Background
The HTLV-1 integrase enzyme shares important struc-
tural similarities with the HIV-1 integrase. Experimental
studies have demonstrated that styrylquinolines and
diketo acids can inhibit both HIV-1 and HTLV-1 inte-
grases. Raltegravir is the only approved integrase inhibi-
tor for the treatment of HIV infection. No data exist
about its potential benefit in HTLV-1 carriers.
Methods
A series of HTLV-1 individuals on regular follow-up at
two Spanish clinics were invited to participate in a pilot
trial in which raltegravir 40 mg bid was administered
for 12 months. Proviral DNA was measured using a vali-
dated real-time PCR assay that targets the HTLV-1 pol
region on PBMCs at baseline and periodically during
follow-up. Demographics and clinical signs/symptoms
were closely monitored in all patients.
Results
A total of 5 HTLV-1 individuals entered the study.
Their country of origin was Peru (2), Ecuador (1),
Dominican Republic (1) and Colombia (1). Their median
age was 52-years old. Three were women. All were
infected with HTLV-1 subtype a subgroup a transconti-
nental. Route of contagion was heterosexual contact in
3, Transfusion in 1 and homosexual relationships in 1.
The latest was coinfected with HIV-1. Two patients had
TSP/HAM whereas the other 3 were asymptomatic.
Median proviral load was 1,658 HTLV-1 DNA copies
per 10,000 PBMC in symptomatic patients compared to
758 copies in asymptomatic individuals. Following initia-
tion of raltegravir therapy and up to 6 months, TSP
patients experienced a transient decline in HTLV-1
proviral load (from 2,248 to 519 and from 1,033 to 861
copies per 10,000 PBMC, respectively). However, a
return to baseline levels was seen in subsequent deter-
minations, being proviral load at 12 months of 2,219
and 1,175, respectively. No improvement in clinical
manifestations could be recognised. No significant
changes in HTLV-1 proviral load were noticed in the 3
asymptomatic individuals with median proviral load
values over time fluctuating around 755 copies /10,000
PBMCs.
Conclusions
Treatment with raltegravir may produce a transient
decline in HTLV-1 proviral load in TSP/HAM patients,
which is not seen in asymptomatic carriers. However,
there is no improvement in TSP/HAM clinical manifes-
tations nor sustained virological benefit beyond six
months of therapy.
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